



Press release

Ad hoc announcement pursuant to Art. 53 LR

## **Update regarding upcoming Annual General Meeting – Change in the Composition of the Board of Directors**

**Tel Aviv / Zurich / New York, February 5, 2024** - SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced that in connection with its upcoming 2023 Annual General Meeting of Shareholders (the "Meeting") to be held on Thursday, February 8, 2024, each of Erez Nachtomy, David Salton, Erez Alroy and our Co-Chairman Ehud Barak, current members of the Company's Board of Directors, have decided not to seek re-election at the Meeting.

As set forth in the Notice and Proxy Statement filed by the Company in connection with the Meeting, as also filed with the Securities and Exchange Commission on December 28, 2023, proposal 2 on the agenda of the Meeting is the approval of the re-election of our six current directors (not including the Company's two external directors, Yehoshua (Shuky) Abramovich and Dvora Kimhi, whose terms of office are not expiring at the Meeting and who are not up for reelection at the Meeting), which includes each of the four directors mentioned above, as well as our Co-Chairman Yariv Alroy and Professor Amir Lerman.

As also set forth in the Notice and Proxy Statement, proposals 3 and 4 on the agenda of the Meeting is the approval of the election of each of our new director-nominees Ido Nouburger and Nir Rotenberg, respectively, and our Board has recommended that shareholders approve the election of the new director-nominees.

In light of the proposed election of the new director-nominees, and in an attempt to further the goal of continuously refreshing the Company's Board of Directors, each of Erez Nachtomy, David Salton and Erez Alroy have decided not to seek re-election, and accordingly, their nominations for re-election will be withdrawn at the Meeting. Mr. Nachtomy will remain as the Company's Chief Executive Officer and will remain engaged with the Board of Directors and benefit from the different perspectives, experience, and qualifications that the new director-nominees will bring to the Board if elected. Mr. Barak has decided not to seek re-election as a director in order to pursue different professional and personal interests and not due to any disagreement with the Company, and accordingly his nomination for re-election will also be withdrawn at the Meeting.

Except as set forth above, there are no changes to the agenda of the Meeting and the Meeting will proceed as schedule, and the Company will not be amending and re-circulating a revised Notice and Proxy Statement.

### **About SHL Telemedicine**

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet



communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).

For more information, please visit our website at [www.shl-telemedicine.com](http://www.shl-telemedicine.com).

## **Contacts**

Fabienne Farner, IRF, Phone : +41 43 244 81 42, [farner@irf-reputation.ch](mailto:farner@irf-reputation.ch)

## **Forward-Looking Statements**

*Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements*